Evidence map›Paper›PMID 32102665›Full record

ArticleCell communication and signaling : CCS2020

Keap1-targeting microRNA-941 protects endometrial cells from oxygen and glucose deprivation-re-oxygenation via activation of Nrf2 signaling.

Shu-Ping Li, Wei-Nan Cheng, Ya Li, Hong-Bin Xu, Hui Han, Ping Li, Deng-Xia Zhang

Open access · goldAbstract readVideo-Audio Media
In one paragraph

Article in Cell communication and signaling : CCS, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. The Keap1-Nrf2 System: A Mediator between Oxidative Stress and Aging.Oxidative medicine and cellular longevity · 2021
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Shu-Ping LiObstetrics and Gynecology Department, the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, No. 188 Gehu Lake Road, Wujin District, Changzhou, Jiangsu, China.
Wei-Nan ChengDepartment of Orthopedics, The First Affiliated Hospital of Xiamen University, Xiamen, China.
Ya LiThe Central Lab, North District, Suzhou Municipal Hospital affiliated to Nanjing Medical University, Suzhou, China.
Hong-Bin XuObstetrics and Gynecology Department, the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, No. 188 Gehu Lake Road, Wujin District, Changzhou, Jiangsu, China.
Hui HanObstetrics and Gynecology Department, the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, No. 188 Gehu Lake Road, Wujin District, Changzhou, Jiangsu, China. drhanhuiey@163.com.ORCID 0000-0001-7697-5910
Ping LiDepartment of Radiotherapy and Oncology, Affiliated Kunshan Hospital of Jiangsu University, Suzhou, China. lipingksfs7@163.com.
Deng-Xia ZhangObstetrics and Gynecology Department, the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, No. 188 Gehu Lake Road, Wujin District, Changzhou, Jiangsu, China. 13919255870@163.com.
Changzhou No.2 People's Hospital · CNFirst Affiliated Hospital of Xiamen University · CNJiangsu University · CNSuzhou Municipal Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMimicking ischemia-reperfusion injury, oxygen and glucose deprivation (OGD)-re-oxygenation (OGDR) applied to endometrial cells produces significant oxidative stress and programmed necrosis, which can be inhibited by nuclear-factor-E2-related factor 2 (Nrf2) signaling. MicroRNA (miRNA)-induced repression of Keap1, a Nrf2 suppressor protein that facilitates Nrf2 degradation, is novel strategy to activate Nrf2 cascade.

methodsMicroRNA-941 (miR-941) was exogenously expressed in HESC and primary human endometrial cells, and the Nrf2 pathway examined by Western blotting and real-time quantitative PCR analysis. The endometrial cells were treated with OGDR, cell programmed necrosis and apoptosis were tested.

resultsMiR-941 is a novel Keap1-targeting miRNA that regulates Nrf2 activity. In T-HESC cells and primary human endometrial cells, ectopic overexpression of miR-941 suppressed Keap1 3'-UTR (untranslated region) expression and downregulated its mRNA/protein expression, leading to activation of the Nrf2 cascade. Conversely, inhibition of miR-941 elevated Keap1 expression and activity in endometrial cells, resulting in suppression of Nrf2 activation. MiR-941 overexpression in endometrial cells attenuated OGDR-induced oxidative stress and programmed necrosis, whereas miR-941 inhibition enhanced oxidative stress and programmed necrosis. MiR-941 overexpression and inhibition were completely ineffective in Keap1-/Nrf2-KO T-HESC cells (using CRISPR/Cas9 strategy). Restoring Keap1 expression, using an UTR-depleted Keap1 construct, abolished miR-941-induced anti-OGDR activity in T-HESC cells. Thus Keap1-Nrf2 cascade activation is required for miR-941-induced endometrial cell protection.

conclusionsTargeting Keap1 by miR-941 activates Nrf2 cascade to protect human endometrial cells from OGDR-induced oxidative stress and programmed necrosis. Video Abstract.

Indexed as

AdultCells, CulturedCell SurvivalEndometriumFemaleHumansKelch-Like ECH-Associated Protein 1MicroRNAsNF-E2-Related Factor 2Oxidative StressPrimary Cell CultureReperfusion InjuryKEAP1 protein, humanKelch-Like ECH-Associated Protein 1MicroRNAsMIRN941 microRNA, humanNFE2L2 protein, humanNF-E2-Related Factor 2Endometrial cellsIschemia-reperfusion injuryKeap1microRNA-941Nrf2

Identifiers

PMID32102665
PMCPMC7045607
OpenAlexW3012948429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.